Dmello, Rhynelle S.
Palmieri, Michelle
Thilakasiri, Pathum S.
Doughty, Larissa
Nero, Tracy L. http://orcid.org/0000-0002-3393-1843
Poh, Ashleigh R. http://orcid.org/0000-0001-8375-4753
To, Sarah Q.
Lee, Erinna F.
Douglas Fairlie, W. http://orcid.org/0000-0002-2498-1160
Mielke, Lisa http://orcid.org/0000-0002-9522-9320
Parker, Michael W. http://orcid.org/0000-0002-3101-1138
Poon, Ivan K. H. http://orcid.org/0000-0002-9119-7173
Batlle, Eduard http://orcid.org/0000-0003-2422-0326
Ernst, Matthias http://orcid.org/0000-0002-6399-1177
Chand, Ashwini L. http://orcid.org/0000-0002-1245-729X
Funding for this research was provided by:
Victorian Cancer Agency (19014)
Cancer Council Victoria (1143036)
Department of Health | National Health and Medical Research Council (1194263, 1166447)
AARP Foundation (11666447)
Victorian Cancer Agency
Article History
Received: 17 January 2023
Revised: 8 March 2024
Accepted: 22 March 2024
First Online: 10 April 2024
Competing interests
: M.E is a shareholder and adviser for Lassen Therapeutics for the development of IL-11 signalling antagonists.